Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.

Chao J, Lin J, Frankel P, Clark AJ, Wiley DT, Garmey E, Fakih M, Lim D, Chung V, Luevanos E, Eliasof S, Davis ME, Yen Y.

J Gastrointest Oncol. 2017 Dec;8(6):962-969. doi: 10.21037/jgo.2017.08.10.

2.

Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.

Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS.

Trends Cancer. 2017 Jul;3(7):529-541. doi: 10.1016/j.trecan.2017.05.002. Epub 2017 Jun 10. Review.

PMID:
28718406
3.

CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.

Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ.

Cancer Res. 2017 Jan 1;77(1):112-122. doi: 10.1158/0008-5472.CAN-15-2951. Epub 2016 Oct 26. Erratum in: Cancer Res. 2017 Dec 1;77(23 ):6790-6791.

4.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8.

5.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

Pham E, Yin M, Peters CG, Lee CR, Brown D, Xu P, Man S, Jayaraman L, Rohde E, Chow A, Lazarus D, Eliasof S, Foster FS, Kerbel RS.

Cancer Res. 2016 Aug 1;76(15):4493-503. doi: 10.1158/0008-5472.CAN-15-3435. Epub 2016 Jun 20.

6.

Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.

Svenson S, Case RI, Cole RO, Hwang J, Kabir SR, Lazarus D, Lim Soo P, Ng PS, Peters C, Shum P, Sweryda-Krawiec B, Tripathi S, van der Poll D, Eliasof S.

Mol Pharm. 2016 Mar 7;13(3):737-47. doi: 10.1021/acs.molpharmaceut.5b00608. Epub 2016 Feb 2.

PMID:
26835715
7.

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.

Conley SJ, Baker TL, Burnett JP, Theisen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS.

Breast Cancer Res Treat. 2015 Apr;150(3):559-67. doi: 10.1007/s10549-015-3349-8. Epub 2015 Apr 2.

PMID:
25833208
8.

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.

Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS.

Clin Cancer Res. 2015 Feb 15;21(4):808-18. doi: 10.1158/1078-0432.CCR-14-2810. Epub 2014 Dec 18.

9.

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.

Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, Schluep T, Chao J, Lin J, Yen Y, Han H, Wiley DT, Zuckerman JE, Davis ME.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15127-32. doi: 10.1073/pnas.1309566110. Epub 2013 Aug 26.

10.

CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development.

Young C, Schluep T, Hwang J, Eliasof S.

Curr Bioact Compd. 2011 Mar;7(1):8-14.

11.

Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.

Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S.

J Control Release. 2011 Jul 15;153(1):49-55. doi: 10.1016/j.jconrel.2011.03.007. Epub 2011 Mar 23.

12.

Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics.

Tolliday N, Clemons PA, Ferraiolo P, Koehler AN, Lewis TA, Li X, Schreiber SL, Gerhard DS, Eliasof S.

Cancer Res. 2006 Sep 15;66(18):8935-42.

13.

WAY-855 (3-amino-tricyclo[2.2.1.02.6]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake.

Dunlop J, Eliasof S, Stack G, McIlvain HB, Greenfield A, Kowal D, Petroski R, Carrick T.

Br J Pharmacol. 2003 Nov;140(5):839-46. Epub 2003 Sep 29.

14.

Sulfhydryl modification of V449C in the glutamate transporter EAAT1 abolishes substrate transport but not the substrate-gated anion conductance.

Seal RP, Shigeri Y, Eliasof S, Leighton BH, Amara SG.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15324-9.

15.
16.

Characterization of gamma-aminobutyric acid receptor GABAB(1e), a GABAB(1) splice variant encoding a truncated receptor.

Schwarz DA, Barry G, Eliasof SD, Petroski RE, Conlon PJ, Maki RA.

J Biol Chem. 2000 Oct 13;275(41):32174-81. Erratum in: J Biol Chem 2001 Mar 23;276(12):9582.

17.

Localization and function of five glutamate transporters cloned from the salamander retina.

Eliasof S, Arriza JL, Leighton BH, Amara SG, Kavanaugh MP.

Vision Res. 1998 May;38(10):1443-54.

18.

Excitatory amino acid transporters of the salamander retina: identification, localization, and function.

Eliasof S, Arriza JL, Leighton BH, Kavanaugh MP, Amara SG.

J Neurosci. 1998 Jan 15;18(2):698-712.

19.

Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance.

Arriza JL, Eliasof S, Kavanaugh MP, Amara SG.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4155-60.

20.

Rapid AMPA receptor desensitization in catfish cone horizontal cells.

Eliasof S, Jahr CE.

Vis Neurosci. 1997 Jan-Feb;14(1):13-8.

PMID:
9057264
21.

Retinal glial cell glutamate transporter is coupled to an anionic conductance.

Eliasof S, Jahr CE.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4153-8.

22.
23.

Neural interactions mediating the detection of motion in the retina of the tiger salamander.

Werblin F, Maguire G, Lukasiewicz P, Eliasof S, Wu SM.

Vis Neurosci. 1988;1(3):317-29.

PMID:
2856477
24.

Supplemental Content

Loading ...
Support Center